Tumor necrosis factor-alpha-regulated transporters

Tumor necrosis factor-alpha-regulated transporters refer to a diverse set of membrane proteins whose expression and activity are specifically modulated by the pro-inflammatory cytokine TNF-alpha [1]. This group includes critical proteins such as the drug efflux pump P-glycoprotein (ABCB1), glucose transporters like GLUT1, and various solute carriers like monocarboxylate transporter 1 (MCT1) and iron transporters (DMT1, IREG1) [1, 2, 3]. The modulation typically occurs via TNF-alpha binding to its primary receptor, TNFR1, which activates downstream signaling pathways such as NF-kappaB and MAPK to alter gene transcription and protein trafficking [1, 4]. In chronic inflammatory conditions like rheumatoid arthritis and inflammatory bowel disease, dysregulation of these transporters can impair nutrient absorption and significantly alter drug pharmacokinetics [2, 3]. For instance, TNF-induced overexpression of P-glycoprotein at the blood-brain barrier can restrict the entry of therapeutic agents into the central nervous system, leading to treatment resistance [1]. Therapeutically, these transporters are indirectly targeted by anti-TNF agents, including monoclonal antibodies like infliximab and adalimumab [4, 5]. By neutralizing TNF-alpha, these drugs can restore the physiological expression levels of the dependent transporters, improving tissue homeostasis and therapeutic drug delivery [1, 5]. Monitoring biomarkers like C-reactive protein and serum TNF-alpha levels helps clinicians assess the impact of treatment on this regulatory axis [4]. Overall, understanding the role of TNF-alpha in transporter regulation is crucial for managing metabolic dysfunction and optimizing pharmacotherapy in inflammatory diseases [2, 3].

Other names

TNF-alpha dependent transportersTNF-modulated transportersTNF-alpha sensitive transportersTNF-alpha-regulated solute carriers

Neutralization of soluble and transmembrane TNF-alpha to prevent its binding to TNFR1/TNFR2 receptors, thereby inhibiting downstream signaling pathways (such as NF-kappaB and MAPK) that transcriptionally regulate the expression and activity of various membrane transporters.